TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Amneal Pharmaceuticals
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease

Amneal Pharmaceuticals reported promising interim results from its ELEVATE-PD study for CREXONT, a new extended-release Parkinson's disease treatment. The study showed significant improvements in patient 'Good On' time, reduced 'Off' time, and enhanced motor symptom control across 55 patients.

Insights
AMRX   positive

Reported strong interim clinical trial results demonstrating substantial improvements in Parkinson's disease treatment, highlighting potential breakthrough in a field with limited recent innovation